
ABSTRACT Background Lichong decoction, a classic Chinese herbal formula, has been applied to treat gynecological diseases and abdominal masses. According to pathogenesis of gastric cancer, we add some Chinese herbs to form the formula of modified Lichong decoction (MLCD) for treatment gastric carcinoma. Aim To investigate the effect of MLCD on inhibiting proliferation and inducing apoptosis, and to explore its molecular mechanisms through metabolomics and pharmacological validation in AGS gastric cancer cells. Methods The CCK‐8 assay, bromodeoxyuridine (BrdU) staining, morphological observation, DNA gel electrophoresis, and Annexin V‐FITC/PI staining were employed to evaluate the pharmacological effect of MLCD. The potential molecular mechanism of MLCD was evaluated by metabolomics and pharmacological verification. Results The pharmacological effects showed that MLCD could inhibit proliferation, induce apoptosis, and affect the expression of apoptosis‐related genes and proteins (Bcl‐2, Bim, Bax, Fas, and FasL) in AGS cells. The metabolomics results verified that multiple signalling/metabolic pathways, including the PI3k/Akt signalling pathway, were involved in MLCD‐treated AGS cells. Subsequently, we conducted a pharmacological verification by combining with LY294002. The results showed that MLCD could reduce the protein expression levels of p‐Akt and p‐FoxO3a and enhance the nuclear translocation of FoxO3a. All results revealed that combining with LY294002 had more significant pharmacological effects. Meanwhile, the synthetical results of previous network pharmacology verified the related targets of MLCD for anti‐gastric cancer. The results showed that MLCD could reduce the gene and protein expression of P53, P21, LKB1, and AMPK in AGS cells. Conclusion MLCD could suppress proliferation and induce apoptosis in AGS cells, which may involve the mitochondrial apoptotic pathway, death receptor pathway, P53/P21 pathway, LKB1/AMPK pathway, and PI3k/Akt pathway.
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly progressive paraparesis, sensory disturbance, urinary retention, B symptoms, and bulky lymphadenopathy. Baseline white blood cell count was 2.30 × 10 9 /L, absolute lymphocyte count 1.48 × 10 9 /L, hemoglobin 82 g/L, platelet count 157 × 10 9 /L, and β2‐microglobulin 8.3 mg/L. CSF flow cytometry identified 46.31% abnormal monoclonal mature small B cells, and IgH/IgK rearrangements were detected. Whole‐spine magnetic resonance imaging showed abnormalities involving the lower medulla oblongata and spinal cord. After dexamethasone and intrathecal chemotherapy, zanubrutinib 160 mg twice daily was initiated in April 2023; venetoclax was started later that month at 20 mg daily and escalated weekly to 400 mg daily. Independent ambulation was restored by Month 3. At Month 4, marrow and CSF cytology/flow cytometry were negative and the largest abdominal mass had decreased from 11.0 × 6.4 to 1.3 × 0.9 cm. Low‐level CSF measurable residual disease (MRD), assessed by flow cytometry through detection of 57 phenotypically abnormal monoclonal mature small B cells (2.22% of nucleated cells), was detected in June 2024 and became negative after lumbar puncture and intrathecal therapy in November 2024. PET/CT in December 2024 showed a Deauville score of 2. Venetoclax was discontinued in April 2025 after approximately 2 years of combination therapy, and zanubrutinib monotherapy was continued. At final follow‐up in April 2026, the patient remained clinically stable with normal bowel and bladder function; marrow and CSF examinations were negative, and brain and whole‐spine MRI showed no intracranial or intraspinal tumor involvement. Blood counts remained generally stable, and no clinically significant toxicity was documented. Conclusion This case supports further investigation of zanubrutinib plus venetoclax as the systemic component of a multimodal treatment strategy for CNS‐involved CLL/SLL. Because corticosteroid and intrathecal therapy were administered concomitantly, and because this is a single case, the independent efficacy and general safety of the oral combination cannot be established.
ABSTRACT Background Epithelial ovarian cancer (EOC) exhibits substantial heterogeneity in clinical outcomes, highlighting the need for diverse prognostic tools. Transforming growth factor‐β‐induced protein (TGFBIp) has been implicated in ovarian cancer progression, but its incremental prognostic value within machine learning frameworks remains unexplored. Aims To develop and validate machine learning models incorporating TGFBIp expression to predict vital status and recurrence in EOC patients. Methods and Results We analyzed 155 EOC patients from a tissue microarray. TGFBIp expression in tumor cells and stroma was assessed by immunohistochemistry. Twelve machine learning algorithms were benchmarked across four feature inclusion strategies, with TGFBIp expression sequentially added to a baseline clinicopathological model. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) with bootstrap 95% confidence intervals, the area under the precision‐recall curve, calibration intercept and slope, Brier score, and decision curve analysis (DCA). The incremental value of TGFBIp was formally tested by paired bootstrap comparison of test‐set AUCs. SHAP analysis was performed for model interpretation. The support vector machine (SVM) with Strategy 4 (incorporating both tumor and stromal TGFBIp) was selected for vital status prediction, achieving a test‐set AUC of 0.951 (95% CI 0.870–0.998), accuracy of 0.872, sensitivity of 0.920, specificity of 0.818, and negative predictive value (NPV) of 0.900. The random forest (RF) with Strategy 4 was selected for recurrence prediction, achieving a test‐set AUC of 0.936 (95% CI 0.816–1.000), sensitivity of 0.974, and NPV of 0.800. Adding TGFBIp features significantly improved vital status prediction (ΔAUC +0.038, 95% CI +0.002 to +0.092 for Strategy 4 vs. baseline). Calibration was acceptable for the vital status model (test‐set calibration intercept −0.24, slope 1.25, Brier score 0.071). SHAP analysis identified maximum tumor diameter, grade, stage, and TGFBIp expression as leading predictors; tumoral TGFBIp contributed to both outcomes, whereas stromal TGFBIp contributed mainly to vital status prediction. DCA suggested potential clinical utility across a broad range of threshold probabilities. Conclusion We established a machine learning framework incorporating compartment‐specific TGFBIp expression for EOC prognosis. TGFBIp in tumor cells provided incremental prognostic information beyond conventional clinicopathological parameters.
ABSTRACT Background Multi‐cancer detection assays may extend early‐detection efforts beyond organ‐specific screening programs and support emerging models of oncologic primary care, including age‐ and risk‐stratified multi‐cancer screening. We evaluated urine volatile organic compound profiles (volatome), an emerging biomarker source, for its association with cancer detection. Objective To determine whether urinary volatome profiles measured by gas chromatography–mass spectrometry (GC–MS) and interpreted with artificial intelligence (AI) distinguish participants with known cancer from cancer‐free controls and support exploratory tissue‐of‐origin (TOO) and stage classification. Methods This multicenter retrospective case–control discovery study included urine from 491 treatment‐naive participants with one of 10 cancers each and 200 cancer‐free healthy controls. Three participating sites contributed de‐identified specimens. Volatome profiles were measured by GC–MS. A proprietary ensemble tree‐based AI pipeline underwent repeated stratified fivefold internal cross‐validation. Preprocessing was fitted within each training partition. Each participant contributed one sample and was assigned only once within a given fold partition. The reported cancer‐signal operating point targeted 98% specificity. TOO analysis identified the most likely cancer type and its presumed tissue of origin. Results The cancer‐signal classifier produced an out‐of‐fold area under the receiver operating characteristic curve (AUC) of 0.990 (95% confidence interval [CI], 0.984–0.996). At the reported 98% specificity‐optimized cutoff, sensitivity was 91.9% (451/491). The positive predictive value (PPV) was 99.1% with the cohort's 71% (491/691) cancer prevalence. Grouped TOO accuracy was 91.6% (450/491; 95% CI, 89.2%–94.1%). Among 374 cancers with a recorded stage, the early‐versus‐late detection classifier had an AUC of 0.866, and it correctly assigned 98.1% (252/257) of early‐stage cancers to the early class while recovering 25.6% (30/117) of the late‐stage cancers. Recursive removal with high feature importance values produced a small, gradual decline rather than an abrupt loss of performance across the evaluated classification tasks. Conclusions Urinary VOC profiles contained a composite signal that discriminated known cancer cases from cancer‐free controls under internal cross‐validation with signals that were able to identify TOO with reasonable certainty. The feature‐removal analysis was consistent with distributed predictive information rather than reliance on one dominant VOC or a small feature panel. Prospective blinded validation in the intended‐use population remains necessary to establish population‐screening accuracy, comparative superiority, or clinical utility.
ABSTRACT Background Sarcomatoid intrahepatic cholangiocarcinoma (sICC) is a rare and highly aggressive variant of intrahepatic cholangiocarcinoma. Due to overlapping clinical and imaging features, it is frequently misdiagnosed as benign hepatic lesions, such as bacterial liver abscesses. Case Herein, we report a case of a 59‐year‐old male patient who presented with fever and right upper abdominal pain. Laboratory tests revealed markedly elevated inflammatory markers. Ultrasound‐guided percutaneous drainage was performed, and Hafnia alvei was cultured from the purulent fluid. Combined with abscess‐like imaging manifestations and tumor necrosis with possible secondary infection, the case was preoperatively misdiagnosed as a bacterial liver abscess. The patient underwent a laparoscopic partial hepatectomy. Intraoperative frozen‐section pathology suggested a hepatic malignant tumor, and the final postoperative diagnosis confirmed sICC with well‐differentiated squamous cell carcinoma. Despite aggressive surgical intervention, the patient's condition rapidly deteriorated with imaging suggestive of tumor progression, and he died of multiple organ failure approximately 10 weeks after the initial surgery. Conclusion This case underscores the diagnostic pitfall of sICC presenting as a liver abscess. Puncture or drainage of such necrotic masses should be performed with caution due to the risk of tumor cell dissemination. Early recognition, timely biopsy, and aggressive radical resection are crucial for improving the prognosis of this rare entity.